Parameters to assess the necessity of adjuvant therapy for early‐stage oral squamous cell carcinoma
Oral Diseases · 2025
DOI: 10.1111/odi.15123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oral Diseases, 2025. Verfasst von Hsueh-Ju Lu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan. Hauptthemen laut MEDLINE: Mouth Neoplasms, Carcinoma, Squamous Cell, Chemoradiotherapy, Adjuvant. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Chung Shan Medical University Hospital.
Abstract (Originalsprache)
Objective
One‐third of head and neck squamous cell carcinomas are early‐stage oral cavity squamous cell carcinomas (OCSCC). Despite a high curative rate, 20% of early‐stage OCSCC patients do not achieve long‐term survival. This study evaluates the role of adjuvant therapy (ADJ) in delaying disease progression and prolonging survival.
Methods
This single‐institute retrospective cohort study enrolled 481 early‐stage OCSCC patients, 16% (78/481) of whom received ADJ. It was reported according to the STROBE guidelines. Cox proportional hazards regression and Kaplan–Meier survival curves were employed to identify suitable candidates for ADJ.
Results
The 5‐year locoregional recurrence‐free survival (LR‐RFS) and overall survival rates were 73.2% and 84.9%, respectively. Positive margins and advanced depth of invasion (DOI) were independent predictors of LR‐RFS. For patients with positive margins, adjuvant chemoradiotherapy (CRT) was superior to adjuvant radiotherapy alone in improving LR‐RFS (hazard ratios for adjuvant CRT vs. none, 0.042; adjuvant radiotherapy alone vs. none, 0.702). Excluding positive margins, advanced DOI was the most critical factor in assessing the need for ADJ. Positive margins and advanced DOI were more appropriate criteria than EORTC 22931/RTOG 9501 for evaluating adjuvant CRT.
Conclusions
Adjuvant CRT was indicated for patients with positive margins and advanced DOI to improve survival outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematology and Oncology, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan.
- School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
- Department of Dentistry, Chung Shan Medical University Hospital, Taichung, Taiwan.
- School of Dentistry, Chung Shan Medical University, Taichung, Taiwan.
- Department of Radiation Oncology, Chung Shan Medical University Hospital, Taichung, Taiwan.
- Department of Otolaryngology, Chung Shan Medical University Hospital, Taichung, Taiwan.
ORCID-Profile: Hsueh-Ju Lu, Shun-Fa Yang
Förderung
- Chung Shan Medical University Hospital
Zitieren
APA
Lu, H. J., Chiu, Y. W., Peng, C. Y., Tseng, H. C., Hsin, C. H., Chuang, C. Y., Fan, S., Huang, W. S., & Yang, S. F. (2025). Parameters to assess the necessity of adjuvant therapy for early‐stage oral squamous cell carcinoma. Oral Diseases. https://doi.org/10.1111/odi.15123
Vancouver
Lu HJ, Chiu YW, Peng CY, Tseng HC, Hsin CH, Chuang CY, et al. Parameters to assess the necessity of adjuvant therapy for early‐stage oral squamous cell carcinoma. Oral Diseases. 2025. doi:10.1111/odi.15123
BibTeX
@article{Lu2025,
author = {Lu, Hsueh-Ju and Chiu, Yu-Wei and Peng, Chih-Yu and Tseng, Hsien-Chun and Hsin, Chung-Han and Chuang, Chun-Yi and Fan, Sheng and Huang, Wei-Shiou and Yang, Shun-Fa},
title = {Parameters to assess the necessity of adjuvant therapy for early‐stage oral squamous cell carcinoma},
journal = {Oral Diseases},
year = {2025},
doi = {10.1111/odi.15123}
}
EUVIMED